BAM
PCVX icon

Belpointe Asset Management’s Vaxcyte PCVX Stock Holding History

Belpointe Asset Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-148
Closed -$5.55K – 2521
2023
Q1 		$5.55K Buy
+148
New +$6.28K ﹤0.01% 2968

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Belpointe Asset Management's PCVX Position: Q2 2023 in Review

Belpointe Asset Management sold out of Vaxcyte (PCVX) in Q2 2023, closing a stake of 148 shares — an estimated $5.55K sold.

Belpointe Asset Management first reported a position in PCVX in Q1 2023 and held it in 1 quarter. The position peaked at $5.55K in Q1 2023. 197 funds tracked by Wall St. Rank hold PCVX as of Q2 2023.

  • Belpointe Asset Management reported no remaining Vaxcyte position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 148 Vaxcyte shares in Q2 2023, an estimated $5.55K.
  • Belpointe Asset Management first reported a position in Vaxcyte in Q1 2023 and held it in 1 quarter.
  • Belpointe Asset Management's Vaxcyte position peaked at $5.55K in Q1 2023.
  • 197 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.